Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05970718
Registration number
NCT05970718
Ethics application status
Date submitted
24/07/2023
Date registered
1/08/2023
Date last updated
17/04/2024
Titles & IDs
Public title
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
Query!
Scientific title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN7544, an Antagonistic Monoclonal Antibody to NPR1, in Healthy Adults
Query!
Secondary ID [1]
0
0
R7544-HV-22109
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - REGN7544
Treatment: Drugs - Matching Placebo
Experimental: IV Dose Level 1 - Randomized 6:2 for single ascending IV dose
Experimental: IV Dose Level 2 - Randomized 6:2 for single ascending IV dose
Experimental: IV Dose Level 3 - Randomized 6:2 for single ascending IV dose
Experimental: IV Dose Level 4 - Randomized 6:2 for single ascending IV dose
Experimental: IV Dose Level 5 - Randomized 6:2 for single ascending IV dose
Experimental: IV Dose Level 6 - Randomized 6:2 for single ascending IV dose
Experimental: SC Dose Level 1 - Randomized 6:2 for single ascending SC dose
Experimental: SC Dose Level 2 - Randomized 6:2 for single ascending SC dose
Experimental: SC Dose Level 3 - Randomized 6:2 for single ascending SC dose
Experimental: Optional Cohort 1 - Randomized 6:2 for single ascending dose This is an optional cohort, that may be IV or SC and will not exceed highest dose level
Experimental: Optional Cohort 2 - Randomized 6:2 Randomized 6:2 for single ascending dose This is an optional cohort, that may be IV o SC and will not exceed highest dose level
Treatment: Drugs: REGN7544
Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
Treatment: Drugs: Matching Placebo
Solution for single ascending IV or SC administration per the protocol
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of Treatment Emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Through approximately day 162
Query!
Primary outcome [2]
0
0
Severity of TEAEs
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Through approximately day 162
Query!
Secondary outcome [1]
0
0
Changes from baseline in Systolic Blood Pressure (SBP)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Through day 6
Query!
Secondary outcome [2]
0
0
Changes from baseline in Diastolic Blood Pressure (DBP)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Through day 6
Query!
Secondary outcome [3]
0
0
Changes from baseline in Mean Arterial Pressure (MAP)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Through day 6
Query!
Secondary outcome [4]
0
0
Changes from baseline in Pulse Pressure (PP)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Through day 6
Query!
Secondary outcome [5]
0
0
Concentrations of REGN7544 in serum over time
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Through approximately day 162
Query!
Secondary outcome [6]
0
0
Incidence of treatment-emergent Anti-Drug Antibody (ADA)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Through approximately day 162
Query!
Secondary outcome [7]
0
0
Titer of ADA
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Through approximately day 162
Query!
Eligibility
Key inclusion criteria
Key
1. Has a body mass index between 18 and 32 kg/m^2
2. Is judged by the investigator to be in good health based on medical history, physical
examination, vital sign measurements, and electrocardiograms (ECGs) performed at
screening and/or prior to administration of initial dose of study drug, as defined in
the protocol
3. Has normal blood pressure (BP) and pulse rate readings, as defined in the protocol
4. Difference between semi-recumbent systolic blood pressure (SBP) measurements in left
and right arm less than 20 mmHg at screening visit
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
1. History of clinically significant cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as
assessed by the investigator that may confound the results of the study or poses an
additional risk to the participant by study participation
2. History, in the past 2 years of a diagnosis of hypertension, symptomatic hypotension
(BP <90/50 mmHg with associated symptoms), symptomatic orthostatic hypotension,
postural orthostatic tachycardia syndrome, syncope, or clinically significant cardiac
arrhythmia
3. Presents any concern to the study investigator that might confound the results of the
study or poses an additional risk to the participant by their participation in the
study
4. Was hospitalized (ie, >24 hours) for any reason within 30 days of screening
5. Is a current smoker or former smoker, including e-cigarettes, who stopped smoking
within 3 months prior to screening
NOTE: Other protocol defined inclusion / exclusion criteria apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
7/08/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
11/09/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
80
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Christchurch
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Regeneron Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is researching an experimental drug called REGN7544.The study is focused on healthy
adults. The aim of the study is to see how safe and tolerable the study drug is in healthy
adults.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in your blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less
effective or could lead to side effects)
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05970718
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trial Management
Query!
Address
0
0
Regeneron Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05970718
Download to PDF